Pulse Biosciences Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Pulse Biosciences te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Medical Equipment winstgroei	17.5%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?

Jan 20

Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication

Jan 12

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Dec 16

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Pulse Biosciences onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

NasdaqCM:PLSE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2024	N/A	-46	-34	-34	N/A
6/30/2024	N/A	-44	-36	-35	N/A
3/31/2024	N/A	-43	-36	-36	N/A
12/31/2023	N/A	-42	-33	-33	N/A
9/30/2023	0	-39	-34	-34	N/A
6/30/2023	0	-47	-35	-34	N/A
3/31/2023	0	-51	-38	-38	N/A
12/31/2022	1	-59	-47	-47	N/A
9/30/2022	2	-65	-52	-52	N/A
6/30/2022	2	-61	-55	-54	N/A
3/31/2022	2	-62	-59	-58	N/A
12/31/2021	1	-64	-55	-54	N/A
9/30/2021	1	-62	-51	-51	N/A
6/30/2021	N/A	-61	-46	-46	N/A
3/31/2021	N/A	-57	-38	-37	N/A
12/31/2020	N/A	-50	-36	-35	N/A
9/30/2020	N/A	-50	-35	-35	N/A
6/30/2020	N/A	-49	-35	-35	N/A
3/31/2020	N/A	-49	-37	-36	N/A
12/31/2019	N/A	-47	-35	-34	N/A
9/30/2019	N/A	-42	-32	-31	N/A
6/30/2019	N/A	-41	-30	-30	N/A
3/31/2019	N/A	-39	-26	-26	N/A
12/31/2018	N/A	-38	-24	-24	N/A
9/30/2018	N/A	-37	-22	-22	N/A
6/30/2018	N/A	-34	N/A	-18	N/A
3/31/2018	N/A	-31	N/A	-14	N/A
12/31/2017	N/A	-26	N/A	-11	N/A
9/30/2017	N/A	-20	N/A	-9	N/A
6/30/2017	N/A	-15	N/A	-8	N/A
3/31/2017	N/A	-11	N/A	-9	N/A
12/31/2016	N/A	-10	N/A	-8	N/A
9/30/2016	N/A	-8	N/A	-7	N/A
6/30/2016	N/A	-6	N/A	-6	N/A
3/31/2016	N/A	-4	N/A	-4	N/A
12/31/2015	N/A	-3	N/A	-3	N/A
9/30/2015	N/A	-2	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van PLSE boven de spaarquote ( 2.5% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van PLSE naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van PLSE naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van PLSE naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van PLSE naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PLSE naar verwachting over 3 jaar hoog zal zijn

Pulse Biosciences Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates fall by 31%

Consensus forecasts updated

Price target decreased to US$11.17

Consensus forecasts updated

Price target decreased to US$35.33

Price target decreased to US$35.33

Recent updates

Pulse Biosciences, Inc. Announces Positive Clinical Data Presented At the American Thyroid Association

Pulse Biosciences, Inc. Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Pulse Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Pulse Biosciences, Inc. announced delayed 10-Q filing

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Small Cap Comp Value Index

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought US$86k worth of stock

Pulse Biosciences Stock: Signs Of Life Following Q1 Update

Pulse Biosciences, Inc Announces CEO Changes

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

New major risk - Financial position

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman exercised options to buy US$382k worth of stock.

Executive Chairman recently bought US$1.1m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought US$105k worth of stock

Executive Chairman exercised options to buy US$68k worth of stock.

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Executive Chairman exercised options to buy US$881k worth of stock.

Executive Chairman exercised options to buy US$36m worth of stock.

Independent Director exercised options to buy US$543k worth of stock.

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Strategy Officer & Director recently bought US$70k worth of stock

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

Pulse Biosciences, Inc. Announces Executive Changes

Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO

Consensus revenue estimates fall by 31%

Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System

Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index

Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million.

Consensus forecasts updated

Price target decreased to US$11.17

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc

Consensus forecasts updated

Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky

Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022

Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission

Price target decreased to US$35.33

Price target decreased to US$35.33

Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

Forecast to breakeven in 2024

Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?

Consensus forecasts updated

Price target decreased to US$37.95

Independent Chairman of the Board recently bought US$50m worth of stock